Literature DB >> 3263444

The international standard for human interleukin-2. Calibration by international collaborative study.

A J Gearing1, R Thorpe.   

Abstract

Three lyophilized preparations of interleukin-2 coded 86/500, 86/564 and 86/504 have been evaluated in an international collaborative study for their suitability as an international standard. All of the preparations performed well in the different bioassay systems included in the study, and showed excellent stability on accelerated temperature degradation. Material similar to that in preparation 86/504 has served well as an interim reference reagent for interleukin-2 for 3 years. Therefore with the agreement of the study participants and the authorization of the Expert Committee on Biological Standardization of the World Health Organization, the preparation coded 86/504 was established in 1987 as the 1st international standard for interleukin-2, with a defined potency of 100 IU/ampoule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263444     DOI: 10.1016/0022-1759(88)90145-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.

Authors:  Zulmarie Perez Horta; Swetha Saseedhar; Alexander L Rakhmilevich; Lakeesha Carmichael; Jacquelyn A Hank; Margaret Boyden; Stephen D Gillies; Paul M Sondel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

2.  Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids.

Authors:  P Purasiri; A Mckechnie; S D Heys; O Eremin
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

3.  Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.

Authors:  E Huland; H Heinzer; H Huland
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 4.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

5.  A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.

Authors:  L T Vlasveld; E M Rankin; A Hekman; S Rodenhuis; J H Beijnen; A M Hilton; A C Dubbelman; F A Vyth-Dreese; C J Melief
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

6.  Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity.

Authors:  Aner Ottolenghi; Priyanka Bolel; Rhitajit Sarkar; Yariv Greenshpan; Muhammed Iraqi; Susmita Ghosh; Baisali Bhattacharya; Zoe V Taylor; Kiran Kundu; Olga Radinsky; Roi Gazit; David Stepensky; Ron N Apte; Elena Voronov; Angel Porgador
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

7.  The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected].

Authors:  R C Stein; V Malkovska; S Morgan; A Galazka; C Aniszewski; S E Roy; R J Shearer; R A Marsden; D Bevan; E C Gordon-Smith
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

Review 8.  Improving Immunotherapy Through Glycodesign.

Authors:  Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.